Strengthening Patient Safety: The Launch of the Biovigilance Programme of India
GS2GS3
The Ministry of Health and Family Welfare has launched the Biovigilance Programme of India, spearheaded by the Indian Pharmacopoeia Commission, to monitor and mitigate adverse events in organ and tissue transplantation.
The Ministry of Health and Family Welfare has officially approved the Biovigilance Programme of India, a critical policy intervention designed to enhance the safety standards of the nation’s transplant ecosystem. To be implemented under the aegis of the Indian Pharmacopoeia Commission (IPC), this initiative marks a significant shift toward a more robust, data-driven regulatory framework for biological products used in medical procedures.
Historically, pharmacovigilance in India has primarily focused on pharmaceutical drugs. However, the increasing complexity of organ and tissue transplantation necessitates a specialized surveillance mechanism. The Biovigilance Programme aims to systematically monitor, report, and analyze adverse events associated with biological products—such as tissues, cells, and organs—throughout the entire transplant lifecycle. By covering both donors and recipients, the programme seeks to identify potential risks, such as the transmission of infectious diseases or immunological reactions, thereby ensuring higher clinical outcomes and patient safety.
Continue reading — free with login
JeetoBharat publishes daily UPSC current affairs mapped to the Mains syllabus. Log in to read full articles.
Log in to read full articleNo credit card required. Free registered users get unlimited access.
This article was curated using AI. While we strive for accuracy, please verify critical facts from official sources.